Category - Developments

Developments

UNITY Biotech posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related macular degeneration (AMD) for...

July 6, 2021

Developments

Titan posts positive results in first studies of TP-2021 implant in chronic pruritus

Titan Pharmaceuticals (NASDAQ:TTNP) reported that an in vivo study of its ProNeura-based human kappa-opioid receptor agonist, TP-2021, implant in an established itch-induced mouse model has demonstrated the...

June 23, 2021

Developments

CymaBay presents positive PBC data at the International Liver Congress

CymaBay Therapeutics (NASDAQ:CBAY) announced positive data at The International Liver Congress from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary...

June 21, 2021

Developments

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

A peer-reviewed paper authored by clinicians and researchers from Germany’s ALTA Klinik and the University Hospital, LMU Munich, and published in Urologic Oncology illustrates that Profound Medical’s...

June 21, 2021

Developments

atai Life Sciences prices $225-million IPO

atai Life Sciences (NASDAQ:ATAI) priced an initial public offering of 15 million common shares at $15 each for gross proceeds of $225-million. In its first day of trading on June 18, the stock jumped $4.45, or 29%, to...

June 18, 2021

Developments

Versant, RA Capital launch LENZ Therapeutics in $47-million series A

A $47-million series A financing from Versant Ventures and RA Capital Management launched LENZ Therapeutics, with a lead late-stage clinical program for presbyopia. Proceeds from the financing will be used to progress...

June 17, 2021

Developments

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Clearside Biomedical (NASDAQ:CLSD) reported positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX, an axitinib injectable suspension, which is administered by suprachoroidal...

June 15, 2021

Developments

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Lucid Psycheceuticals inked a world-wide license agreement with Toronto’s University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications...

June 14, 2021

Developments

Hepion Pharmaceuticals to be added to the Russell Microcap Index

Hepion Pharmaceuticals (NASDAQ:HEPA) is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28. Membership in the...

June 9, 2021

Developments

Veterinary healthcare company evaluating IntelGenx VetaFilm platform

IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a materials transfer agreement with an undisclosed global veterinary healthcare company to evaluate IntelGenx’s proprietary VetaFilm platform in cats. Based on a...

June 8, 2021

Category - Developments

UNITY Biotech posts positive Phase 1 data in advanced vascular eye disease

Titan posts positive results in first studies of TP-2021 implant in chronic pruritus

CymaBay presents positive PBC data at the International Liver Congress

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

atai Life Sciences prices $225-million IPO

Versant, RA Capital launch LENZ Therapeutics in $47-million series A

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Hepion Pharmaceuticals to be added to the Russell Microcap Index

Veterinary healthcare company evaluating IntelGenx VetaFilm platform

General

More